Toshirou Nishida. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Adenocarcinoma/drug therapyAdenocarcinoma/mortalityAdenocarcinoma/secondaryAdministration, OralAntimetabolites, Antineoplastic/adverse effectsAntimetabolites, Antineoplastic/therapeutic useAntineoplastic Combined Chemotherapy Protocols/adverse effectsAntineoplastic Combined Chemotherapy Protocols/therapeutic useCamptothecin/administration & dosageCamptothecin/analogs & derivativesCisplatin/administration & dosageDisease-Free SurvivalDrug Administration ScheduleDrug CombinationsFluorouracil/adverse effectsFluorouracil/therapeutic useHumansInfusions, IntravenousIrinotecanJapan/epidemiologyOxonic Acid/adverse effectsOxonic Acid/therapeutic usePatient SelectionRisk AssessmentStomach Neoplasms/drug therapyStomach Neoplasms/mortalityStomach Neoplasms/secondaryTegafur/adverse effectsTegafur/therapeutic useTime FactorsTreatment Outcome
Substances: See more » Antimetabolites, AntineoplasticDrug CombinationsS 1 (combination)TegafurOxonic AcidIrinotecanCisplatinFluorouracilCamptothecin
Year: 2009 PMID: 19880057 DOI: 10.1016/S1470-2045(09)70322-5
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316